

Quris-AI

Isaac Bentwich, Gaya Margalit Quris-AI * Website- quris.ai* CEO name- Dr. Isaac Bentwich

CATEGORY: Pharma or Medical Devices or Health SESSIONS: •

Is AI revolutionizing drug discovery and clinical development? • Israeli medical contribution to breakthrough science and technology

- o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. Quris-AI's innovative Bio-AI platform merges AI with patient-on-a-chip technology, offering a groundbreaking solution to the pharmaceutical industry's high drug development failure rates and reliance on animal testing. With key partnerships, including a successful pilot with Merck KGaA, and a focus on safety prediction, QurisAI is set to transform drug discovery, reducing costs and accelerating the development of safe, personalized treatments.

- o Core Technology What is the technology, its uniqueness, and its value proposition? Quris-AI's core technology uniquely integrates advanced AI algorithms with patienton-a-chip models, simulating human organ responses to drugs. This innovative blend allows for precise safety assessments, drastically cutting down the drug development failure rate. By providing a closer approximation to human physiology than animal models, it offers significant value in developing safer, more effective treatments with reduced time and cost.

- o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. Quris-AI's BioAI platform, pivotal in its pipeline, is set to transform drug development and tackle the pharmaceutical industry's \$13 billion annual losses from failed trials. Strategic partnerships with giants like MerckKGAA amplify its market potential, positioning Quris-AI to significantly lower trial failures and redefine the efficiency of bringing new, safe drugs to market.

- o Business Strategy - Short-term revenues will stem from collaborations and safety assessments. Longterm, Quris plans to expand its genomic diversity and global lab presence, driving broader adoption in pharma alliances, personalized drug safety services, and potentially licensing its predictive technology for wider industry use.

- o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans Quris-AI is advancing its R&D by enhancing the BioAI platform, focusing on integrating broader genomic diversity and refining predictive accuracy. Preclinical efforts will expand through partnerships, aiming to transition successful predictions into clinical trials. Organizationally, Quris plans to scale its global lab network, fostering closer collaborations. Financially, the focus is on securing further investment for R&D expansion, scaling operations, and accelerating market penetration through strategic pharma alliances.